Dr Stephen Mattarollo, Research Fellow
Dr Stephen Mattarollo, Research Fellow

View ResearcherID Page

Dr Mattarollo is a cancer immunologist, with a strong interest in developing combination immunotherapies for blood cancers.

 

Mattarollo joined the research group led by Professor Ian Frazer at The University of Queensland Diamantina Institute in 2007 to undertake postdoctoral research, investigating immune regulation in animal models of cervical cancer.

Mattarollo furthered his training in the field of cancer immunotherapy by secondment to the laboratory of Professor Mark Smyth at the Peter MacCallum Cancer Centre in Melbourne (2010-2012). There, he and his group developed a novel therapeutic cancer vaccine for B cell lymphomas, and through collaboration with international colleagues in France, made significant inroads into understanding how the immune system is required for effective chemotherapy treatment outcomes in cancer patients.

Returning to UQDI in May 2012, Mattarollo established his own group with the vision and goal to develop blood cancer immunotherapies at the Translational Research Institute and UQDI. His interest currently lies with translation focused pre-clinical research. Mattarollo’s team fundamentally investigates combination immune-based therapies for blood cancers with focus on developing a novel therapeutic cancer vaccine against non-hodgkin's lymphoma. The approach is centred on the concept that multi-modality therapy for cancer that incorporates immunotherapeutic strategies to initiate or enhance anti-tumor immunity will be most effective for achieving durable clinical responses and improving patient outcomes. The longer-term objective is to improve treatment quality and outcomes for patients with advanced cancers through translation-directed immunological research.

Another expanding theme of his group's research is investigating how chronic psychological stress impacts upon immune system function and how this subsequently affects both the development of cancer and responses to cancer therapies. The goal of this research is to identify the consequences of chronic stress on immune function and cancer progression to provide evidence for complementary treatment approaches that aim to reduce stress and minimize its impact on this disease.

 

 

Email: s.mattarollo@uq.edu.au
Phone: +617 3443 6985

Open Access

UQDI Collection

All in UQ eSpace

Top 10 recent publications:

  1. Tran, Le Son, Mittal, Deepak, Mattarollo, Stephen R. and Frazer, Ian H. (2015) Interleukin-17A promotes arginase-1 production and 2,4-dinitrochlorobenzene-induced acute hyperinflammation in human papillomavirus E7 oncoprotein-expressing skin. Journal of Innate Immunity, 7 4: 392-404. doi:10.1159/000374115
  2. Abd Warif, Nor Malia, Stoitzner, Patrizia, Leggatt, Graham R., Mattarollo, Stephen R., Frazer, Ian H. and Hibma, Merilyn H. (2015) Langerhans Cell Homeostasis and Activation Is Altered in Hyperplastic Human Papillomavirus Type 16 E7 Expressing Epidermis. PLoS One, 10 5: e0127155-e0127155. doi:10.1371/journal.pone.0127155
    Kobayashi T, Doff B.L, Rearden R.C, Leggatt G.R and Mattarollo S.R. NKT cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma. Oncoimmunology (2015) Jan 7; 3;e990793.
  3. Gosmann C, Frazer I.H, Blumenthal A* and Mattarollo S.R*. IL-18, but not IL-12, induces production of IFN-gamma in the immunosuppressive environment of HPV16 E7 transgenic hyperplastic skin. J Invest Dermatol. (2014) Oct; 134(10); 2562-9. *Equal contribution.
  4. Ma Y, Mattarollo S.R., Adjemian S, et al., CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. Cancer Res. (2014) Jan 15; 74(2): 436-45.
  5. Ma Y, Adjemian S, Mattarollo S.R, et al., Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity (2013) Apr18;38(4):729-41.
  6. Mattarollo S.R, Steegh K, Li M, Duret H, Ngiow S.F, and Smyth M.J. Transient Foxp3+ regulatory T cell depletion enhances therapeutic anti-cancer vaccination targeting the immune-stimulatory properties of NKT cells. Immunol Cell Biol (2012) Oct 23. doi: 10.1038/icb.2012.58.
  7. Mattarollo S.R, West A, Steegh K, Duret H, Paget C, Martin B, Matthews G, Shortt J, Chesi M, Leif Bergsagel P, Bots M, Zuber J, Lowe S, Johnstone R and Smyth M.J. NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven B cell lymphoma. Blood (2012) Oct 11; 120(15): 3019-3029.
  8. Mattarollo S.R, Yong M, Gosmann C, Choyce A, Chan D, Leggatt GR, Frazer IH. NKT cells inhibit antigen-specific effector CD8 T cell induction to skin viral proteins. J Immunol. (2011) Jul 8; 187(4):1601-1608.
  9. Mattarollo S.R, Loi S, Duret H, Ma Y, Zitvogel L, Smyth MJ. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res. Jul 15;71(14):4809-4820 (2011).
  10. Ma Y, Aymeric L, Locher C, Mattarollo S.R, Delahaye N.F, Pereira P, Boucontet L, Apetoh L, Ghiringhelli F, Casares N, Lasarte J.J, Matsuzaki G, Ikuta K, Ryffel B, Benlagha K, Tesnière A, Ibrahim N, Déchanet-Merville J, Chaput N, Smyth M.J, Kroemer G and Zitvogel L. Contribution of IL-17-producing gamma/delta T cells to the efficacy of anticancer chemotherapy. J Exp Med. Mar 14;208(3):491-503. (2011).

 

  • Therapeutic vaccination strategies targeting blood cancers.
  • Combination immunotherapies against haematological malignancies.
  • Mechanisms of tumor resistance against immune-based therapies.
  • The effect of chronic stress on immune surveillance and immunotherapy of cancer.
  • Immunosuppressive myeloid cell populations in lymphoma/leukaemia.

 

 

Go to top